Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S18 pseudogene 13 is a processed pseudogene derived from the ribosomal protein S18 gene, located in the human genome. Pseudogenes like RPS18P13 originate from retrotransposition or duplication events, resulting in non-functional gene copies that typically lack regulatory elements or are disrupted by mutations[1][8][13]. While the parent gene, ribosomal protein S18, is an essential component of the small 40S ribosomal subunit involved in protein synthesis[4][7], RPS18P13 does not contribute to ribosome structure or function and is generally considered biologically inert[8][13]. The parent gene, RPS18, is vital for protein synthesis and associated with diseases like Diamond-Blackfan Anemia when mutated[7]. As a pseudogene, RPS18P13 has no known protein product, biological activity, disease role, biomarker utility, or drug interactions[1][5][13]. Pseudogenes sometimes serve as markers of genomic evolution or may be used in genomic studies, but do not serve as therapeutic targets[8]. Pseudogene annotation (e.g., "ribosomal protein S18 pseudogene 13") strictly indicates non-coding DNA lacking a productive role in cell biology[1][2][5][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S18 pseudogene 13 (RPS18P13).